Abstract |
In this paper we describe advances in the clinical development of antiepileptic drugs as a function of the Antiepileptic Drug Development Program of the National Institute of Neurological and Communicative Disorders and Stroke. This program encompasses both the preclinical and clinical elements of drug development through the Anticonvulsant Screening Project, the Toxicology Project, and the support of controlled clinical trials of potential new drugs that emerge from these projects and promise to be more effective and less toxic than those currently available for the treatment of epilepsy.
|
Authors | R J Porter, B J Hessie, J J Cereghino, G D Gladding, H J Kupferberg, B Scoville, B G White |
Journal | Federation proceedings
(Fed Proc)
Vol. 44
Issue 10
Pg. 2645-9
(Jul 1985)
ISSN: 0014-9446 [Print] United States |
PMID | 3891417
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
|
Topics |
- Animals
- Anticonvulsants
(history, therapeutic use)
- Clinical Trials as Topic
- Dogs
- Drug Evaluation
(history)
- Drug Evaluation, Preclinical
- Humans
- Mice
- National Institutes of Health (U.S.)
- Random Allocation
- Rats
- United States
- United States Food and Drug Administration
|